Geisslinger G, Menzel S, Wissel K, Brune K
Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Germany.
Br J Clin Pharmacol. 1995 Jul;40(1):73-5. doi: 10.1111/j.1365-2125.1995.tb04537.x.
The pharmacokinetics of the enantiomers of ketoprofen after oral administration of 12.5 mg, 25 mg and 50 mg and i.v. administration of 50 mg racemic ketoprofen to 24 healthy subjects were investigated. The AUC values of R- (r2 = 0.929) and S-ketoprofen (r2 = 0.930) were proportional to dose. The absolute bioavailability of the 50 mg oral dose was 84.5 (s.d. 20.6) % and 81.4 (18.0) % for R-ketoprofen and S-ketoprofen, respectively. With the exception of AUC values no dose dependent differences in pharmacokinetic parameters were observed. However, the R-enantiomer had higher AUC, lower clearance data and higher Cmax values than the S-form after oral administration. The results suggest that stereochemical and pharmacokinetic considerations cannot explain the lack of dose response observed with ketoprofen doses below 50 mg.
对24名健康受试者口服12.5毫克、25毫克和50毫克酮洛芬对映体以及静脉注射50毫克消旋酮洛芬后的药代动力学进行了研究。R-酮洛芬(r2 = 0.929)和S-酮洛芬(r2 = 0.930)的AUC值与剂量成正比。50毫克口服剂量的R-酮洛芬和S-酮洛芬的绝对生物利用度分别为84.5(标准差20.6)%和81.4(18.0)%。除AUC值外,未观察到药代动力学参数的剂量依赖性差异。然而,口服给药后,R-对映体的AUC更高,清除率数据更低,Cmax值比S-型更高。结果表明,立体化学和药代动力学因素无法解释低于50毫克酮洛芬剂量时观察到的剂量反应缺乏现象。